Chronic Lymphocytic Leukaemia (CLL) is an extremely heterogeneous haematological neoplasm of B-lymphocytes. Some patients never require therapy whilst others frequently relapse, partly attributable to recurrent genomic aberrations of prognostic significance identified by Next Generation Sequencing (NGS). Recently, the implementation of targeted gene panel NGS in CLL in their clinical setting has improved prognostication of patients.
Recent publication of the National Institute for Clinical Excellence guidelines for improving outcomes in haematological cancer (NG47 guidelines) and the publication of the national genomic test directory within the UK promote the harmonisation of testing pathways available to patients across the United Kingdom.
One sample will be issued per round (1 round per year). Participants will be asked to test the sample with their relevant in house CLL panel and report any clinically relevant intragenic and/or regulatory elemnt changes such as point mutations, small insertion, deletion and duplication events. Participants will not be requested to report larger changes affecting genome architecture or copy number changes (>50kb).